MIR107, microRNA 107, 406901

N. diseases: 123; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0019193
Disease: Hepatitis, Toxic
Hepatitis, Toxic 		0.300 Biomarker disease CTD_human "Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human." 28545106 2017
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease 		0.300 Biomarker phenotype CTD_human "Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human." 28545106 2017
CUI: C1262760
Disease: Hepatitis, Drug-Induced
Hepatitis, Drug-Induced 		0.300 Biomarker disease CTD_human "Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human." 28545106 2017
CUI: C3658290
Disease: Drug-Induced Acute Liver Injury
Drug-Induced Acute Liver Injury 		0.300 Biomarker disease CTD_human "Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human." 28545106 2017
CUI: C4277682
Disease: Chemical and Drug Induced Liver Injury
Chemical and Drug Induced Liver Injury 		0.300 Biomarker disease CTD_human "Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human." 28545106 2017
CUI: C4279912
Disease: Chemically-Induced Liver Toxicity
Chemically-Induced Liver Toxicity 		0.300 Biomarker disease CTD_human "Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human." 28545106 2017
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.100 Biomarker disease BEFREE MiR-107 is reduced in Alzheimer's disease brain neocortex: validation study. 20413881 2010
CUI: C0524851
Disease: Neurodegenerative Disorders
Neurodegenerative Disorders 		0.020 Biomarker group BEFREE miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease. 20489155 2010
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.040 Biomarker phenotype BEFREE miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. 21841313 2011
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.020 Biomarker disease BEFREE miR-107: a toll-like receptor-regulated miRNA dysregulated in obesity and type II diabetes. 22645244 2012
CUI: C0017638
Disease: Glioma
Glioma 		0.090 Biomarker disease BEFREE MicroRNA-107 inhibits glioma cell migration and invasion by modulating Notch2 expression. 23299462 2013
CUI: C0017638
Disease: Glioma
Glioma 		0.090 Biomarker disease BEFREE MicroRNA-107 inhibits U87 glioma stem cells growth and invasion. 23572380 2013
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.050 Biomarker disease BEFREE MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. 25197016 2014
CUI: C4722085
Disease: Malignant neoplasm of colon and/or rectum
Malignant neoplasm of colon and/or rectum 		0.020 Biomarker disease BEFREE MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. 25197016 2014
CUI: C0023418
Disease: leukemia
leukemia 		0.010 Biomarker disease BEFREE miR‑107 promotes the erythroid differentiation of leukemia cells via the downregulation of Cacna2d1. 25373460 2015
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia 		0.010 Biomarker disease BEFREE miR‑107 promotes the erythroid differentiation of leukemia cells via the downregulation of Cacna2d1. 25373460 2015
CUI: C0278701
Disease: Gastric Adenocarcinoma
Gastric Adenocarcinoma 		0.020 Biomarker disease BEFREE miR-107 and miR-25 simultaneously target LATS2 and regulate proliferation and invasion of gastric adenocarcinoma (GAC) cells. 25824045 2015
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.010 AlteredExpression disease BEFREE miR-107 promotes hepatic lipid accumulation by suppressing transcript levels of HADHA, induces hyperglycemia and impairs glucose tolerance. 26499439 2016
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms 		0.010 PosttranslationalModification group BEFREE MiR-107 suppresses the proliferation of hepatoma cells by targeting HMGA2 mRNA. 27773820 2016
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE MiR-107 is downregulated and has a tumor suppressive effect in breast cancer, likely through regulation via its inverted downstream target of BDNF. 27813254 2017
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.010 AlteredExpression group BEFREE MiR-107 was markedly downregulated in both breast cancer cell lines and breast tumors. 27813254 2017
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.100 AlteredExpression phenotype BEFREE MiR-107 overexpression was markedly suppressed with respect to in vitro breast cancer proliferation, cell cycle progression and invasion, as well as with respect to in vivo development of breast cancer xenograft. 27813254 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.040 Biomarker phenotype BEFREE miR-107 regulates tumor progression by targeting NF1 in gastric cancer. 27827403 2016
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.020 Biomarker disease BEFREE miR-107 Promotes Proliferation and Inhibits Apoptosis of Colon Cancer Cells by Targeting Prostate Apoptosis Response-4 (Par4). 27938501 2017
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.020 Biomarker disease BEFREE miR-107 Promotes Proliferation and Inhibits Apoptosis of Colon Cancer Cells by Targeting Prostate Apoptosis Response-4 (Par4). 27938501 2017